188 related articles for article (PubMed ID: 15613443)
1. Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy.
Nicholson RI; Staka C; Boyns F; Hutcheson IR; Gee JM
Endocr Relat Cancer; 2004 Dec; 11(4):623-41. PubMed ID: 15613443
[TBL] [Abstract][Full Text] [Related]
2. Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies.
Nicholson RI; Hutcheson IR; Britton D; Knowlden JM; Jones HE; Harper ME; Hiscox SE; Barrow D; Gee JM
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):257-62. PubMed ID: 15860268
[TBL] [Abstract][Full Text] [Related]
3. [Hormone resistance and its modulation in breast cancer].
Kahán Z; Thurzó L
Orv Hetil; 2005 Apr; 146(16):731-7. PubMed ID: 15889669
[TBL] [Abstract][Full Text] [Related]
4. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.
Massarweh S; Schiff R
Clin Cancer Res; 2007 Apr; 13(7):1950-4. PubMed ID: 17404074
[TBL] [Abstract][Full Text] [Related]
5. Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model.
Staka CM; Nicholson RI; Gee JM
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S85-97. PubMed ID: 16113102
[TBL] [Abstract][Full Text] [Related]
6. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
Massarweh S; Schiff R
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
[TBL] [Abstract][Full Text] [Related]
7. Membrane-initiated steroid signaling action of estrogen and breast cancer.
Song RX
Semin Reprod Med; 2007 May; 25(3):187-97. PubMed ID: 17447208
[TBL] [Abstract][Full Text] [Related]
8. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
[TBL] [Abstract][Full Text] [Related]
9. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
Schiff R; Massarweh SA; Shou J; Bharwani L; Arpino G; Rimawi M; Osborne CK
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():10-20. PubMed ID: 16273359
[TBL] [Abstract][Full Text] [Related]
10. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor: current understanding of its activation and modulation.
Osborne CK; Schiff R; Fuqua SA; Shou J
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4338s-4342s; discussion 4411s-4412s. PubMed ID: 11916222
[TBL] [Abstract][Full Text] [Related]
12. Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations.
Gururaj AE; Rayala SK; Vadlamudi RK; Kumar R
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1001s-1007s. PubMed ID: 16467116
[TBL] [Abstract][Full Text] [Related]
13. Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer.
Nicholson RI; Gee JM
Br J Cancer; 2000 Feb; 82(3):501-13. PubMed ID: 10682656
[No Abstract] [Full Text] [Related]
14. Endocrine-responsive breast cancer and strategies for combating resistance.
Ali S; Coombes RC
Nat Rev Cancer; 2002 Feb; 2(2):101-12. PubMed ID: 12635173
[TBL] [Abstract][Full Text] [Related]
15. New approaches to reverse resistance to hormonal therapy in human breast cancer.
Weinberg OK; Marquez-Garban DC; Pietras RJ
Drug Resist Updat; 2005 Aug; 8(4):219-33. PubMed ID: 16054421
[TBL] [Abstract][Full Text] [Related]
16. Resistance to endocrine therapy in breast cancer.
Kurebayashi J
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():39-46. PubMed ID: 16273353
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches.
Moy B; Goss PE
Clin Cancer Res; 2006 Aug; 12(16):4790-3. PubMed ID: 16914563
[TBL] [Abstract][Full Text] [Related]
18. Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?
Bedard PL; Freedman OC; Howell A; Clemons M
Breast Cancer Res Treat; 2008 Apr; 108(3):307-17. PubMed ID: 18351454
[TBL] [Abstract][Full Text] [Related]
19. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer.
Nicholson RI; Hutcheson IR; Hiscox SE; Knowlden JM; Giles M; Barrow D; Gee JM
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S29-36. PubMed ID: 16113097
[TBL] [Abstract][Full Text] [Related]
20. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
Lewis JS; Jordan VC
Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
